
Matinas BioPharma Holdings Inc (NASDAQ:MTNB) shares are trading higher by 10.4% at $0.86 after the company and BioNTech announced an exclusive research collaboration to evaluate novel delivery technology for mRNA-based vaccines.
Matinas BioPharma says the exclusive collaboration combines BioNTech's mRNA vaccine development expertise and Matinas' Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines, including a potential formulation for oral vaccines.